A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4- ...

We all know the vital precautions to keep babies safe from respiratory syncytial virus (RSV). While the virus is the leading ...

Although this year saw a decrease in both rainfall and average temperature from May to September in comparison to last year, ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Current methods to deliver bacteria to the bladder are invasive and require repeated catheter insertion. Even when bacteria ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.